Sentry Investment Management LLC Decreases Position in Edwards Lifesciences Corp (EW)

Sentry Investment Management LLC cut its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 2.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,203 shares of the medical research company’s stock after selling 351 shares during the period. Sentry Investment Management LLC’s holdings in Edwards Lifesciences were worth $2,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lindbrook Capital LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $27,000. Nelson Roberts Investment Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $30,000. Laurel Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $32,000. AlphaMark Advisors LLC raised its position in shares of Edwards Lifesciences by 281.8% in the fourth quarter. AlphaMark Advisors LLC now owns 210 shares of the medical research company’s stock worth $32,000 after acquiring an additional 155 shares during the period. Finally, We Are One Seven LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $33,000. Institutional investors own 82.79% of the company’s stock.

Get Edwards Lifesciences alerts:

In related news, VP Donald E. Bobo, Jr. sold 5,500 shares of the company’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $177.75, for a total transaction of $977,625.00. Following the completion of the sale, the vice president now owns 24,482 shares of the company’s stock, valued at approximately $4,351,675.50. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Catherine M. Szyman sold 1,474 shares of the company’s stock in a transaction dated Thursday, February 21st. The shares were sold at an average price of $176.34, for a total transaction of $259,925.16. Following the sale, the vice president now directly owns 15,905 shares of the company’s stock, valued at approximately $2,804,687.70. The disclosure for this sale can be found here. Insiders have sold 139,106 shares of company stock valued at $21,894,554 in the last three months. Corporate insiders own 1.84% of the company’s stock.

EW has been the subject of a number of analyst reports. Citigroup upped their price objective on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the stock a “sell” rating in a research report on Wednesday, January 2nd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $180.00 to $190.00 in a research report on Friday, January 18th. Cowen set a $190.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Monday, December 10th. Deutsche Bank initiated coverage on shares of Edwards Lifesciences in a research report on Wednesday, January 2nd. They issued a “hold” rating and a $164.00 price objective for the company. Finally, Credit Suisse Group began coverage on shares of Edwards Lifesciences in a research report on Monday, December 17th. They issued an “outperform” rating and a $188.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $170.38.

EW stock opened at $169.29 on Friday. The stock has a market cap of $35.84 billion, a PE ratio of 36.02, a P/E/G ratio of 2.23 and a beta of 0.92. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.61 and a quick ratio of 1.92. Edwards Lifesciences Corp has a 52 week low of $123.00 and a 52 week high of $178.68.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, January 31st. The medical research company reported $1.17 EPS for the quarter, hitting analysts’ consensus estimates of $1.17. The business had revenue of $977.70 million during the quarter, compared to analysts’ expectations of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same quarter in the previous year, the company earned $0.94 earnings per share. As a group, equities analysts anticipate that Edwards Lifesciences Corp will post 5.21 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sentry Investment Management LLC Decreases Position in Edwards Lifesciences Corp (EW)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/4188932/sentry-investment-management-llc-decreases-position-in-edwards-lifesciences-corp-ew.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Read More: What are Closed-End Mutual Funds?